icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
eNrlWF1v2jAUfedXRHl3EiiUMgWqjbUbUqsxWrRpL5VxLmBm7NQflO7Xz0noRqdEbUP90r0gY8f3XtvnnHvt+HS7Zt4GpKKC9/1mEPkecCISyhd9f3p9jk7800EjXuEN3vusG0RBs+V7hGGl+n42GswAcxV8v7z4CHY+SH/Q8GIxWwHRj74zmrLgM1bLS5xm33jxRtDEW4NeiqTvp0bnvV6stLRRDO6E/KlSTCAOdz37o6ub9n5/HGbGnmHVKJAXmC9KjQKvZZMYKYHrIdawEPK+It6jWrapmoASRhIYY70cS7GhCSSlLuaYKajlZH6XXIHcMNCZk1Lj4YqsVS3jeIW3E7gdlQf93o4O9VajCDW7x+1O1G4fHfeieocr97aq/BTsIsL05qjTiXrdXgg8TIDQDNyIo1bUaqOo1Y3ChIQK1igxqBkhQbSYSSiGbRcRjMECUAKIYbTERgOyP0JSnXcqzG0jFVLbBpIwNwolCBMCCqXScoQ8zFWpdY5ZPs+kdGsxlDeYWeNZTbSMM7/MEU6oGj6GuiM/Em6fxGNCVcrwfbBSad2twhLbYZBWkNwtJFvBtbQSyeye/WOfG8bCF0Y93QmYo4gzfRwKw3WFjp1P6m7EUFhebKtPtJ706u0OixTU65n9JXh52hmbGaOkrshaGTSg9HQyqtbYty1PH7CCqXSnT98oT8Sden3d28eZo+jzM2GlRlOZNG9avZPjZqdTm9Y/LKgrsvCZkSKF0CoiVYcI3YjPxaESZ3lSbuqBJW+YIHl1KghmUFGfopr6a5nxUE474547XhcDpUY/nV3XBexXA/L+Kv9bapom/T9Qq5ecXGQ8S4/KwF9OtkJznNxcjCzXsqXWqXoXhkusCq4Fc/kfZL698sfdLc5JjVXUnEX2cBT6rCgLno+Xupx/qgI79Faxm7+7vZT60NLAAedQpAdnIj46e/288PdK4Szs8SMdc+cmL/+xtrrkqgg0s/IK8KBMZM+Vn0srDl/mc1rxolaJyzgsXvMGjTjMXvIGjd/dva7W
cZpznxex5TqVtQLX